Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alastair M Thompson

Showing results (151-160 of 195) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.
NPJ Breast Cancer|June 9, 2021
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trialPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
British Journal of Cancer|June 29, 2022
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer riskMathilde M Almekinders, Tycho Bismeijer, Tapsi Kumar, et al.
JAMA Surgery|May 7, 2025
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical TrialMark Basik, Reena S Cecchini, Jennifer F De Los Santos, et al.
Radiology. Imaging Cancer|July 28, 2023
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast CancerKen-Pin Hwang, Nabil A Elshafeey, Aikaterini Kotrotsou, et al.
NPJ Breast Cancer|October 29, 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
BMC Cancer|May 11, 2022
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancerFlora Nguyen Van Long, Audrey Lardy-Cleaud, Dimitri Carène, et al.
Pageof 20

Showing results (151-160 of 195) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|January 17, 2018
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort studyEllen R Copson, Tom C Maishman, Will J Tapper, et al.
NPJ Breast Cancer|June 9, 2021
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trialPamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
Cancers|March 10, 2022
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast CancerNour Abuhadra, Ryan Sun, Jennifer K Litton, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
British Journal of Cancer|June 29, 2022
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer riskMathilde M Almekinders, Tycho Bismeijer, Tapsi Kumar, et al.
JAMA Surgery|May 7, 2025
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical TrialMark Basik, Reena S Cecchini, Jennifer F De Los Santos, et al.
Radiology. Imaging Cancer|July 28, 2023
A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast CancerKen-Pin Hwang, Nabil A Elshafeey, Aikaterini Kotrotsou, et al.
NPJ Breast Cancer|October 29, 2025
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trialsShelley Potter, Kerry Avery, Rosina Ahmed, et al.
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
BMC Cancer|May 11, 2022
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancerFlora Nguyen Van Long, Audrey Lardy-Cleaud, Dimitri Carène, et al.
Pageof 20